DLL3 and small cell lung carcinoma: For example, a recent study on DLL3-targeted CAR-T cells for small-cell lung cancer (SCLC) demonstrated that circRNA-based CAR constructs enhance CAR expression stability, alleviate early T-cell exhaustion, and increase tumor-killing capacity, suggesting that circRNA-CAR designs may outperform conventional mRNA-CAR approaches (80).